What is the trading symbol and share class for ZyVersa Therapeutics (ZVSA)?

ZyVersa trades under the symbol ZVSA, representing its Common Stock, par value $0.0001 per share. This security is now quoted on the OTC Pink Limited Market following the July 16, 2026 change.

ZyVersa Therapeutics moves to OTC Pink market

Q: What market change did ZyVersa Therapeutics (ZVSA) disclose?

ZyVersa Therapeutics disclosed that its common stock stopped trading on the OTCQB® Venture Market and began trading on the OTC Pink Limited Market, effective July 16, 2026.

Q: When did ZyVersa Therapeutics (ZVSA) begin trading on the OTC Pink Limited Market?

ZyVersa’s common stock began trading on the OTC Pink Limited Market on July 16, 2026. On that date, trading on the OTCQB® Venture Market ceased and shifted to the new over-the-counter tier.

Q: Did ZyVersa Therapeutics (ZVSA) change its state of incorporation or headquarters?

No changes were reported to ZyVersa’s Delaware incorporation or its principal executive offices at 2436 N Federal Hwy, Suite 466, Lighthouse Point, Florida 33064. The disclosure focused on the trading market for its common stock.

Q: Is ZyVersa Therapeutics (ZVSA) identified as an emerging growth company?

Yes. ZyVersa is identified as an emerging growth company under applicable Exchange Act rules. This status appears alongside the disclosure about its common stock’s quotation on the OTC Pink Limited Market.

ZyVersa Therapeutics, Inc. reports a change in the trading venue for its common stock.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

ZyVersa Therapeutics, Inc. reports a change in the trading venue for its common stock. Effective July 16, 2026, the company’s common stock, par value $0.0001 per share and trading under the symbol ZVSA, ceased trading on the OTCQB® Venture Market and commenced trading on the OTC Pink Limited Market.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Par value per share: $0.0001 per share Effective date of market change: July 16, 2026 Commission File Number: 001-41184

3 metrics

Par value per share $0.0001 per share Par value of ZyVersa Therapeutics, Inc. common stock

Effective date of market change July 16, 2026 Date trading moved from OTCQB Venture Market to OTC Pink Limited Market

Commission File Number 001-41184 SEC Commission File Number for ZyVersa Therapeutics, Inc.

Key Terms

OTCQB® Venture Market, OTC Pink Limited Market, emerging growth company

3 terms

OTCQB® Venture Market market

"ceased trading on the OTCQB® Venture Market and commenced trading on"

OTC Pink Limited Market market

"commenced trading on the OTC Pink Limited Market"

OTC Pink Limited Market is an over‑the‑counter trading tier for stocks that are not listed on major exchanges and provide only limited public information about their operations and financials. It matters to investors because lower disclosure increases uncertainty and risk—prices can be volatile and it can be harder to verify value or spot problems, like buying an unlabeled used item at a flea market where you don’t know its history or condition.

emerging growth company regulatory

"meets the definition of an emerging growth company under Rule 12b-2"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What market change did ZyVersa Therapeutics (ZVSA) disclose?

ZyVersa Therapeutics disclosed that its common stock stopped trading on the OTCQB® Venture Market and began trading on the OTC Pink Limited Market, effective July 16, 2026.

When did ZyVersa Therapeutics (ZVSA) begin trading on the OTC Pink Limited Market?

ZyVersa’s common stock began trading on the OTC Pink Limited Market on July 16, 2026. On that date, trading on the OTCQB® Venture Market ceased and shifted to the new over-the-counter tier.

Did ZyVersa Therapeutics (ZVSA) change its state of incorporation or headquarters?

No changes were reported to ZyVersa’s Delaware incorporation or its principal executive offices at 2436 N Federal Hwy, Suite 466, Lighthouse Point, Florida 33064. The disclosure focused on the trading market for its common stock.

Is ZyVersa Therapeutics (ZVSA) identified as an emerging growth company?

Yes. ZyVersa is identified as an emerging growth company under applicable Exchange Act rules. This status appears alongside the disclosure about its common stock’s quotation on the OTC Pink Limited Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/16/2026 - 05:00 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 16, 2026

ZYVERSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41184

86-2685744

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2436 N Federal Hwy, Suite 466

Lighthouse Point, Florida

33064

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code:

(754) 231-1688

	Not Applicable
	(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ZVSA		(1)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(1) The Company’s common stock is quoted on the OTC Pink Limited Market.

Item 8.01 Other Events.

Effective July 16, 2026, ZyVersa Therapeutics, Inc. ceased trading on the OTCQB® Venture Market and commenced trading on the OTC Pink Limited Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 16, 2026	ZYVERSA THERAPEUTICS, INC.

	/s/ Stephen Glover
	Stephen Glover
	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents